The Princeton-based startup said the move was related to “a revenue mix shift within the Noom business" driven by a change in ...

Cramer first pointed to some names he thinks have been unfairly dinged after earnings on Wednesday, including Walt Disney and Uber, which finished the day down 2.44% and 7.56%, re ...

For decades, the US healthcare system has struggled to address the diet-related chronic illnesses affecting nearly half of ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Fluoride not only strengthens teeth and leads to better health overall but also is one tool communities can use to reduce ...

With the food and beverage industry at risk from the rising incidence of GLP-1 households, Wardlaw highlighted the importance of maximising curiosity at the shelf to mitigate the effects of this ...

Protein features in PepsiCo’s portfolio push in both snacks and beverages to embrace consumer interest in health.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...